KiDDiAI was built with clinical accuracy as the foundation. If you’re a nephrologist, renal dietitian, or CKD care team member, here’s what you need to know.
What KiDDiAI Tracks
KiDDiAI monitors the five nutrients most critical to CKD progression:
| Nutrient | Why It Matters |
|---|---|
| Protein | Excess intake accelerates GFR decline; restriction varies by stage and dialysis status |
| Sodium | Key driver of hypertension and fluid retention in CKD |
| Potassium | Risk of hyperkalemia, especially in Stage 4–5 and dialysis patients |
| Phosphorus | Associated with secondary hyperparathyroidism and cardiovascular risk |
| Fluid | Critical for dialysis patients and those with edema or CHF |
The Renal Balance Score (RBS)
KiDDiAI’s core feature is the Renal Balance Score — a 0–100 composite score computed daily across all five pillars above, personalized to the patient’s CKD stage and dialysis status.
Four scoring profiles are applied based on patient parameters:
- Standard CKD — Stage 3–5, no dialysis
- Dialysis — Hemo or peritoneal dialysis
- Fluid-Restricted — CHF/edema without dialysis
- Early Stage — Stage 0–3a (potassium/phosphorus weighted lower)
This means recommendations adapt as the patient’s condition changes — not a one-size-fits-all approach.
Guideline Alignment
KiDDiAI’s nutrient targets and scoring are informed by:
- KDOQI Clinical Practice Guidelines for Nutrition in CKD
- KDIGO 2024 CKD Guidelines
- NKF Kidney Disease Education Resources
Patients can set custom nutrient limits (prescribed by their care team), or fall back to stage-appropriate defaults.
How to Recommend KiDDiAI
- Download the app and explore it yourself — it’s free to try
- Share the App Store or Google Play link with your patient
- Encourage the patient to set their CKD stage and dialysis status in the profile
- If you have prescribed specific nutrient limits, the patient can enter these manually
Questions or Collaboration Inquiries
We welcome feedback from the clinical community. If you’re interested in piloting KiDDiAI with your patient population or have clinical questions, please get in touch.